Assura PLC Appointment of CIO

RNS Number : 3011D

Assura PLC

09 September 2024

 

9 September 2024

Assura plc

Appointment of CIO

Assura plc ("Assura" or the "Company"), the specialist healthcare property investor and developer, has appointed Steven Noble to the newly created role of Chief Investment Officer ("CIO") to support the business' short and long-term growth strategy.

Steven joins the business effective immediately and will be responsible for implementing Assura's investment strategy across all healthcare markets, including delivery of capital recycling initiatives.

Steven was most recently Chief Investment Officer at Atrato Group, the investment adviser to  Atrato Onsite Energy (ROOF) and Supermarket Income REIT (SUPR), where he negotiated and executed over £2 billion of property transactions and played an important role in taking SUPR from IPO to the FTSE250. Prior roles include nine years at Lloyds in origination and risk management with a focus on commercial real estate and KPMG where he qualified as a chartered accountant.

Jonathan Murphy, Assura CEO, said: "Steven's appointment to the newly created role of Chief Investment Officer is an important strategic step for Assura to support our ambitious growth plans. The UK healthcare crisis continues to worsen with an immense need for improved access to healthcare services across the country. These factors are driving demand for infrastructure across an increasingly diverse range of healthcare markets, to which Assura is best placed to respond owning to our market position, sector expertise and capabilities and our strong corporate culture. Steven's skills and expertise will complement those already within the Executive Committee to deliver against this demand and our long-term growth strategy."

Steven Noble, Assura CIO, said: "I'm delighted to be joining Assura at such an exciting time, with the business strategically positioned to capture the significant growth opportunities across broader healthcare markets. The business' recent acquisition of 14 private hospitals and its JV with USS are a clear indication of the group's ambition and I am incredibly excited to be part of Assura's next stage of growth. I look forward to working as part of an exceptionally skilled and experienced team at the UK's leading listed healthcare property investor."

- Ends -

For more information, please contact:

Assura plc	Tel: [phone]
David Purcell, Investor Relations Director	Email: [e-mail]
FGS Global Gordon Simpson	Tel: [phone] Email: [e-mail]

 

Notes to Editors

Assura plc is the UK's leading specialist healthcare property investor and developer. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.

A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7 billion and has a strong track record of growing financial returns and dividends for shareholders.

At Assura we BUILD for health and as the first FTSE 250 certified B Corp we are committed to keeping ESG at the heart of our strategy, creating Healthy Environments (E) and Healthy Communities (S) and maintaining a Healthy Business (G).

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association
Assura plc LEI code: 21380026T19N2Y52XF72

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BOAUPUQGBUPCGAQ